AGENUS INC Payments to Acquire in Process Research and Development
AGENUS INC (AGEN) reported Payments to Acquire in Process Research and Development of $5.00 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-03-18.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment · last filed 2019-03-18
- AGENUS INC payments to acquire in process research and development for the quarter ending 2016-12-31 was $0.00.
- AGENUS INC payments to acquire in process research and development for the quarter ending 2016-09-30 was $0.00.
- AGENUS INC payments to acquire in process research and development for the quarter ending 2016-06-30 was $4.00M.
- AGENUS INC payments to acquire in process research and development for the quarter ending 2016-03-31 was $1.00M.
- AGENUS INC payments to acquire in process research and development for fiscal 2016 was $5.00M.
| Period end | Payments to Acquire in Process Research and Development 3 month | Payments to Acquire in Process Research and Development 6 month | Payments to Acquire in Process Research and Development 9 month | Payments to Acquire in Process Research and Development 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $0.00 derived: sum of 2 quarters · filed 2019-03-18 | $4.00M derived: sum of 3 quarters · filed 2019-03-18 | $5.00M 10-K · filed 2019-03-18 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $4.00M derived: sum of 2 quarters · filed 2017-11-07 | $5.00M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $5.00M 10-Q · filed 2017-08-07 | ||
| 2016-03-31 | $1.00M 10-Q · filed 2017-05-04 | |||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |